Mirador Therapeutics, Inc.

This study tests several new investigational drugs in 140 adults with moderate-to-severe Crohn's disease or ulcerative colitis. The main goals are to check safety and see if the drugs can improve symptoms and reduce gut inflammation seen on camera exams. Participants must have a …

This early-phase study tests the safety and tolerability of a new drug called MT-251 in 70 healthy adults aged 19 to 55. Participants receive either the drug or a placebo to monitor side effects and how the body processes the drug. No treatment benefit is expected; the goal is to…

This early-stage study tests the safety of a new drug called MT-201 in healthy adults aged 19 to 55. Participants receive either the drug or a placebo to check for side effects and how the body processes the drug. The goal is to gather initial safety data before testing in patien…

This early-stage study is testing a new drug, MT-701, in 78 healthy adults aged 19 to 55. The goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects. This study does…